Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer

8 Mar 2012

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 22406760
DOI: 10.1016/j.ygyno.2012.03.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancerPMID 22406760Read ↗

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.Semantic proximity Read ↗

Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancerSemantic proximity Read ↗

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutationSemantic proximity Read ↗

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.Semantic proximity Read ↗

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patientsSemantic proximity Read ↗

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsSemantic proximity Read ↗

Ovarian cancer treatment in mutation carriers/BRCAness.Semantic proximity Read ↗

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapySemantic proximity Read ↗

Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targetsSemantic proximity Read ↗

BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer.Semantic proximity Read ↗

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.Semantic proximity Read ↗

Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.